Partner
Denise's broad experience includes conducting offensive and defensive discovery, drafting and arguing dispositive motions, taking and defending witnesses in court, drafting trial and appellate briefs, conducting U.S. and foreign prosecution, and preparing patent applications and ex parte reexaminations.
Denise has handled matters involving a wide array of technologies with a focus on the pharmaceutical, chemical, biotechnology, and mechanical arts. She has assisted clients in the fields of pharmaceutical products, cosmetics, hair dyes, pesticides, packaging materials, polymeric materials, and drug delivery systems.
Denise's graduate studies focused on alternative synthetic routes to HIV protease inhibitors. Her undergraduate studies focused on synthesis of heterocyclic compounds as potential anti-cancer agents.
In addition to her litigation practice, Denise advises clients on a variety of patent matters, including polymorph issues, Orange-Book listing patents, U.S. and foreign IP portfolio management, freedom to operate, settlement, licensing, and antitrust issues.
Otsuka Pharmaceutical Co., Ltd. v. Sandoz, Inc.
Represented Otsuka in Hatch-Waxman litigations against seven companies seeking FDA approval to market generic copies of Abilify®, which had 2011 sales of over $5.2 billion. The district court found the asserted patent claims valid, enforceable and infringed in November 2010, and enjoined marketing of any generic until April 2015. The Federal Circuit affirmed that holding in May 2012, with Supreme Court Cert subsequently denied.
3:07-cv-01000, D.N.J., Judges Cooper, Goodman, Hughes
11-1126, -1127, Fed. Cir., Judges Lourie, Moore, Reyna
Acorda Therapeutics, Inc. v. Apotex Inc.
2:07-cv-04937, D.N.J., Judges Arleo, Brown, Greenaway
12-1019, Fed. Cir., Judges Lourie, Prost, Wallach
Otsuka Pharmaceutical Co., Ltd. v. Apotex Corp.
1:14-cv-01078, -04671, -02982, -07405, -05878, -06398 -08074 -03306, -06890, -05876, -08077, -03168, -07252, -07105 -05537, -03996, -06158, -04508, -04307, -06397, -07106, -01979, -03445; 1:15-cv-0161, -07584, -01585, -07803, -08830, -05109, -07802, -08955, -01716, -01967, -06353, -08305; 1:16-cv-05288, -05400, -05949, -07705 -02475, -02476, -08284, -05743, -00086, -08085, -00555, -00557, -07346, -06067, -00405, -00424, -05688, -09603; 1:17-cv-02754, -00392, D.N.J., Judges Simandle, Williams
Ferring B.V. v. Watson Laboratories, Inc.
3:11-cv-00481, D. Nev., Judges Cooke, Jones, McKibben
2:15-cv-04222, D.N.J., Judges Chesler, Hayden, Waldor
Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc.
1:04-cv-03521, D. Md., Judges Bennett, Quarles, Sullivan
14-1671, Fed. Cir., Judges Prost, Lourie, Gilstrap
17-1033, Fed. Cir., Judges Prost, Lourie, Taranto
Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc.
3:08-cv-01583, D.N.J., Judges Cooper, Goodman, Hughes
Event
Patent Litigation 2019: Advanced Techniques & Best Practices Patent Litigation 2019: Advanced Techniques & Best Practices
November 13-14, 2019
New York
Event
Patent Resources Group Fall 2019 Advanced Courses Program Patent Resources Group Fall 2019 Advanced Courses Program
October 12-14, 2019
Scottsdale
Prosecution First Blog
Draft Bill Released to Reform Section 101 of the Patent Act Draft Bill Released to Reform Section 101 of the Patent Act
May 28, 2019
Event
2019 Intellectual Property Institute 2019 Intellectual Property Institute
May 3, 2019
Overland Park
Event
Patent Resources Group Advanced Courses (PRG) Patent Resources Group Advanced Courses (PRG)
April 7-12, 2019
Sarasota
Media Mention
Apotex Challenge to Abilify® IP Won't Get High Court Hearing Apotex Challenge to Abilify® IP Won't Get High Court Hearing
January 14, 2013
Law360Press Release
Finnegan Announces New Partners for 2013 Finnegan Announces New Partners for 2013
December 10, 2012
Media Mention
Otsuka Targets Apotex in Latest Suit Over Generic Abilify® Otsuka Targets Apotex in Latest Suit Over Generic Abilify®
September 12, 2012
Law360Press Release
Otsuka Prevails in U.S. Abilify® Patent Appeal Otsuka Prevails in U.S. Abilify® Patent Appeal
May 7, 2012
Media Mention
Otsuka Slaps Amneal with IP Suit over Generic Abilify® Otsuka Slaps Amneal with IP Suit over Generic Abilify®
April 27, 2012
Law360Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.